ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SBTX Skinbiotherapeutics Plc

10.20
0.05 (0.49%)
21 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherapeutics Plc LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.05 0.49% 10.20 10.25 10.60 10.425 10.15 10.15 1,286,917 16:35:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 132k -2.84M -0.0163 -6.39 18.13M

SkinBioTherapeutics PLC Notice of Results

08/03/2024 9:43am

RNS Regulatory News


RNS Number : 1615G
SkinBioTherapeutics PLC
08 March 2024
 

A blue text on a white background Description automatically generated

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Notice of HY results

 

Newcastle, UK - 8 March 2024 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that the Company's interim financial results for the six months to
31 December 2023 will be released on Friday 22 March 2024.

 

The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the Investor Relations section of the Company's website: www.skinbiotherapeutics.com.

 

Stuart Ashman, CEO, and Manprit Randhawa, CFO will provide a live presentation via the Investor Meet Company platform at 12 noon on Friday 22 March 2024.

 

Questions can be submitted pre-event via the Investor Meet Company dashboard up to the day before the meeting or at any time during the live presentation. Investors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited.

 

Investors can sign up to Investor Meet Company for free at www.investormeetcompany.com/companies/skinbiotherapeutics-plc. 

 

 

-Ends-

 

 

For more information please contact:

 

SkinBioTherapeutics plc

Stuart J. Ashman, CEO

Manprit Randhawa, CFO

 

Tel: +44 (0) 191 495 7325

 

Cavendish Capital Markets Limited

(Nominated Adviser & Broker)

Giles Balleny, Dan Hodkinson (Corporate Finance)

Charlie Combe (Broking)

Dale Bellis, Tamar Cranford-Smith (Sales)

 

Tel: +44 (0) 20 7220 0500

 

Instinctif Partners (Media)

Melanie Toyne-Sewell / Jack Kincade

 

Tel: +44 (0) 20 7457 2020

SkinBioTherapeutics@instinctif.com

 

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORGCGDXLXGDGSI

1 Year Skinbiotherapeutics Chart

1 Year Skinbiotherapeutics Chart

1 Month Skinbiotherapeutics Chart

1 Month Skinbiotherapeutics Chart

Your Recent History

Delayed Upgrade Clock